Wells Fargo Starts HealthSpring (HS) at Outperform; Focused on Medicare Advantage
Tweet
Share
E-mailGet Alerts HS Hot Sheet
Price: $55.00 --0%
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
Wells Fargo initiates coverage on HealthSpring (NYSE: HS) with a Outperform. PT range is $53-57.
Wells analyst says, "HealthSpring is focused on Medicare Advantage, which continues to be our favorite sector due to its strong growth potential and managed care’s relatively low penetration rate. HealthSpring has strong physician engagement tools that should allow it to achieve higher quality ratings (and therefore higher payments) as well as lower costs. We believe the Bravo Health transaction should provide a base from which HealthSpring can grow using its established methods of physician engagement and cost control. We estimate 2011 EPS at $4.20 and 2012 EPS at $4.40."
For more ratings news on HealthSpring click here and for the rating history of HealthSpring click here.
Shares of HealthSpring closed at $35.97 yesterday.
Wells analyst says, "HealthSpring is focused on Medicare Advantage, which continues to be our favorite sector due to its strong growth potential and managed care’s relatively low penetration rate. HealthSpring has strong physician engagement tools that should allow it to achieve higher quality ratings (and therefore higher payments) as well as lower costs. We believe the Bravo Health transaction should provide a base from which HealthSpring can grow using its established methods of physician engagement and cost control. We estimate 2011 EPS at $4.20 and 2012 EPS at $4.40."
For more ratings news on HealthSpring click here and for the rating history of HealthSpring click here.
Shares of HealthSpring closed at $35.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Starts Huntington Bancshares (HBAN) at Overweight
- Needham Starts Pulse Biosciences (PLSE) at Buy
- ThinkEquity Starts Deep Isolation Nuclear (DBHL) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
